RBC Capital raised the firm’s price target on Axsome Therapeutics (AXSM) to $140 from $138 and keeps an Outperform rating on the shares as part ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback